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a b s t r a c t
The diagnosis of myocardial necrosis due to acute myocardial infarction (AMI) and other
causes has long been based on the plasma levels of cardiac troponins. Other markers of
myocardial injury such as myoglobin, heart-type fatty acid binding protein, glycogen
phosphorylase isoenzyme BB, or the early and sensitive total stress marker copeptin remain
to be just attractive options used primarily to early rule out AMI and in risk stratiﬁcation.
Recent years have seen the introduction of a routine practice of the high-sensitivity cardiac
troponin assays capable of detecting diagnostic elevations in plasma troponin levels as early
as the ﬁrst hours of myocardial injury. However, this assay tends to identify very often low
plasma troponin levels in primarily noncardiac conditions and also in healthy or apparently
healthy individuals. Hence, this novel technology warrants further study.
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Diagnosis of myocardial necrosis and, hence, diseases such as
acute myocardial infarction (AMI) has in the past decades
become the domain of biochemical diagnostic tools. However,
the potential of biochemical assays is substantially limited by
the need for high sensitivity and speciﬁcity as well as the time
needed and the simplicity of measurement of any of the
markers. Table 1 provides an overview of the biochemical
markers, and both of those are currently being used in clinical
practice and those with the potential to ﬁnd the widespread
acceptance in the future. While some of the markers have
become somewhat obsolete in the meantime, others are
unlikely to be employed in everyday practice. The increasingly
more sensitive assays entail increasingly more challenging
interpretation. Use of individual markers and interpretation of
the values measured require a large body of knowledge and
experience, which continue to expand thus deserving ade-
quate attention.
Cardiac troponins
Given their sensitivity and precision of determination, cardiac
troponins (cTn) currently are and are likely to remain the gold
standard in the diagnosis of myocardial necrosis. There are
two types of cardiac troponins, I (cTnI) and T (cTnT). They are
released exclusively from the myocardium. In the diagnosis of
AMI and cardiovascular risk stratiﬁcation, both troponins
provide equal information [1–3]. Plasma cTn measurement
provides the basis of the Universal deﬁnition of myocardial
infarction published in 2007 as well as its most recent version
during 2012 [4,5]. As cTnT examination is patented by a single
manufacturer, it is globally standardized; however, results ofTable 1 – Biochemical markers of myocardial necrosis and dyn
Marker of necrosis Onset of the
plasma levels
increase (h)
cTnI 2–6 
cTnT 2–6 
hs-cTn I/T 1 
CK-MB mass 3–8 
CK 3–8 
Myoglobin 1–3 
GPBB 0.5 
h-FABP 0.5 
cTnI, cardiac troponin I; cTnT, cardiac troponin T; hs-cTnI/T, high sen
isoenzyme mass; CK, total creatine kinase; GPBB, glycogen phosphorylascTnI are comparable only when using the same assay of a
speciﬁc manufacturer [6]. Using standard methods, cTn should
not be detected in healthy population. For a number of
reasons, very low levels are also detected in healthy
individuals. The diagnostic cut-off point for AMI, the upper
reference limit (URL), is an arbitrary value. In 2007, URL was
deﬁned as the 99th percentile of a normal reference popula-
tion. Optimal precision of determination, as described by the
coefﬁcient of variation, should be ≤10%. The URLs for speciﬁc
kits are indicated by the manufacturer. The high demands
placed on the biochemical accuracy of the assays have led to a
little bit reduced sensitivity. Despite this, when collecting
blood at an appropriate interval since the onset of necrosis, the
sensitivity is close to 100%. However, in the absence of other
attributes of AMI, an increase in cTn levels is only regarded as a
manifestation of myocardial injury. While an increase in cTn
can be detected within 2–4 h, a diagnostically helpful increase
often does not occur until 4–6 h after the event. Release of cTn
from necrotic myoﬁbrils of cardiomyocytes is a gradual
process. This explains why, in the presence of extensive
myocardial necrosis, the plasma levels of cTn could remain
elevated as long as 14 days. The total amount of released cTn
corresponds to the extent of necrosis. Accurate biochemical
assessment of the extent of necrosis would require an integral
of values measured at short time intervals.
Causes of increased plasma troponin levels
The potential causes of increased plasma cTn levels are listed
in Table 2. The diagnosis of AMI is based on the detection of at
least one cTn value higher than URL followed by a decrease,
with the levels returning to a value below URL – depending on
the magnitude of myocardial necrosis – within hours to days
[4,5]. Thus the diagnosis of AMI requires at least two
measurements. In case of protracted elevation of cTn levelsamics of their changes during acute myocardial infarction.
Max. increase – without
reperfusion (h)
Duration of the
increase
12–30 1–10 days
12–75 1–15 days
– –
9–24 1–3 days
8–58 1–4 days
5–8 <12 h
1 <4 h
1–3 –
sitive assay for troponin I or T; CK-MB mass, creatine kinase MB
e isoenzyme BB; h-FABP, heart type fatty acid binding protein.
Table 2 – The causes of increased plasma concentrations
of cardiac troponin.
Prolonged myocardial ischemia
Myocarditis, pericarditis, endocarditis
Heart contusion
Cardioversion, cardiostimulation, endomyocardial biopsy,
arrhythmia ablation
Severe heart failure
Hypertensive emergencies
Tachyarrhythmias, bradyarrhythmias
Aortic stenosis
Hypertrophic cardiomyopathy
Takotsubo syndrome
Stroke, subarachnoid hemorrhage
High doses of catecholamines
Pulmonary embolization, pulmonary hypertension
Aortic dissection
Inﬁltrative diseases – sarkoidosis, amyloidosis, sclerodermia,
hemochromatosis
Severe burns
Rhabdomyolisis
Cardiotoxic medicine (adriamycin, 5-ﬂuorouracil, etc.)
Snake poisons
Severe hypothyreosis
Sepsis, severe respiratory diseases
Severe renal failure
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myocarditis or another long-term cause. Mild elevations of
cTn are very often associated with tachyarrhythmias, severe
heart failure, pulmonary embolism, hypotension or uncon-
trolled hypertension. These elevations are due to a combina-
tion of various mechanisms. Severe heart failure is associated
with an increase in cTn in up to 40% of the cases. More often,
cTn elevations due to heart failure are seen in patients with
coronary heart disease, hypertension, diabetes mellitus and
renal failure. In these conditions, the elevations are associated
with higher mortality rates and early rehospitalization [7]. In
the presence of supraventricular arrhythmias, mild elevations
in cTn frequently occur just within the ﬁrst hours of the onset
of arrhythmia. In pulmonary embolism and pulmonary
hypertension, the increase in cTn levels correlates with the
severity of the condition, magnitude of EKG alterations,
echocardiographic signs of right ventricular overload and,
most importantly, with prognosis. The absence of an increase
in cTn implies virtually zero mortality and a minor risk of
complications. The negative predictive value is in the range of
97–99%. However, cTn elevations may occasionally be detected
also in patients with mild pulmonary embolism. The positive
predictive value is relatively low (34–42%) [8–12]. In addition to
natriuretic peptides, increased cTn may help guide the
selection of patients beneﬁting from thrombolytic therapy.
However, its indication cannot be based solely on this
parameter [13]. A more marked increase in cTn is associated
with takotsubo cardiomyopathy. The reason for this is unclear
and, perhaps, also ambiguous. The suggested action of
elevated levels of circulating catecholamines may also be at
play in stroke and subarachnoidal hemorrhage as mild cTn
elevations are a frequent occurrence. Without clinical man-
ifestations of myocardial ischemia, there is no need to
measure cTn repeatedly to rule out AMI. Perimyocarditis in
most cases results in a mild elevation of cTn. The elevationwould often persist for several days without a decrease or even
continue to increase. The elevations in cTn levels seen in the
presence of cardiac contusion, after cardioversion, endomyo-
cardial biopsy or ablation for arrhythmia are very small.
Elective cardiac pacing results in modest elevation in cTn
above the URL in more than one in three patients; however, the
increase disappears within 24 h [14]. An increased risk of
cardiovascular complications is heralded by mildly elevated
cTn also in sepsis and other serious conditions. However, cTn
elevations associated with these conditions are not a so
reliable prognostic marker.
Troponin determination using high-sensitivity assays
Besides conventional or standard methods of cTn assessment,
high-sensitive cTn assays have recently become available,
referred as hs-TnT and high-sensitive or ultra-sensitive TnI
(hs-TnI) [15]. The cTn is identical. High sensitive is only the
method. The term high-sensitivity assays refers to those
allowing cTn detection in 50–90% of the healthy adults. URL is
the 99th percentile of values determined in a reference group
of healthy individuals with a coefﬁcient of variation <10% as
with standard assays. However, URL is equal to the upper limit
of normal. High-sensitivity assays have gained widespread
acceptance, particularly the patented hs-cTnT assay. The
values determined using hs-cTn in males are slightly higher
compared with that of females [16]. The URL for males and
females is described as 14.5 and 10 ng/l, respectively, being
13.5 ng/l in a mixed population. The differences when using
hs-cTnI are likely to be even greater. The recommendation is to
use units providing results in whole numbers, that is, ng/l in
the SI system, although the pg/ml predominantly used in the
English-language literature are numerically identical.
A mild elevation of hs-cTn is detected in an even larger
spectrum of the patients without AMI as compared with
standard methods, e.g., in the patients with chronic, seem-
ingly stable heart failure or in stable coronary heart disease, in
those taking a variety of drugs or with more serious
inﬂammatory diseases [17,18]. An increase in hs-cTn values
is associated with increased risk of cardiovascular complica-
tions. A question to be answered yet is the beneﬁt of
therapeutic measures in response to these minimal detected
values. However, use of the triple diagnostic cut-off in an effort
to enhance the assay speciﬁcity resulted in subsequent
increased mortality [19]. It is not yet clear whether unstable
angina can occur without being reﬂected in elevated hs-cTn
levels. An undisputed advantage of the high-sensitivity
methods is the earlier detection of increased plasma cTn
levels [20,21]. A diagnostically useful hs-cTn elevation occurs
as early as 1 h since the onset of necrosis. The diagnosis of AMI
can be excluded based on the magnitude of changes in cTn
levels within the ﬁrst hours of the event. The 2011 European
Society of Cardiology guidelines recommend to repeat cTn
examination at an interval of 3 h [22]. A change in cTn levels
(delta) can be expressed as relative (>20%) or absolute. Studies
have suggested that the assessment based on the absolute
change is more reliable. In the case of hs-cTnT, the diagnostic
value of a change is reported to be 9.2 ng/l. Using this cut-off
value, the negative predictive value (NPV) was 97% and the
positive predictive value (PPV) 49%. In a subpopulation of
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diagnostic value was 6.9 ng/l with NPV of 93% and PPV of 83%
[23]. Similar values are also recommended for follow-up
measurement after 1–2 h [24,25]. As a result, AMI can be ruled
out as early as 2–3 h after the onset of the index event [22]. In
patients experiencing earlier recurrence of AMI in the presence
of a persisting increase in cTn, another AMI should be heralded
by another increase in hs-cTn by at least 20% [5]. In risk
stratiﬁcation of cardiovascular complications, hs-cTn has
been shown to be more sensitive than cTn determined by a
standard method [26,27]. However, routine examinations for
the purpose of risk stratiﬁcation without suspected myocardi-
al injury are not recommended.
Increase in cardiac troponins during heavy exertion
Quite often, elevated cTn and, especially, hs-cTn are detected
following an endurance activity such as the marathon race. In
fact, a mildly elevated cTn does not necessarily be a
manifestation of irreversible injury but only of what is referred
to as a metabolic turnover. Myocyte regeneration occurs
throughout our life, and acceleration of this regenerative
process after a bout of exercise resulting in myocyte death may
not imply irreversible myocardial injury [28–31]. What we do
know is that the increase in cTn in trained athletes is smaller
compared to that seen in individuals pursuing recreational
activities. A major increase in hs-cTn is likely to signal an
already inadequate workload for the body.
Cardiac troponins in renal failure
In moderate renal failure, cTnT levels are often mildly elevated,
with the increase being smaller with cTnI levels [32]. The reason
for the increase is not understood. Although the cause remains
unclear, elevated cTn levels correlate signiﬁcantly with the risk
of total mortality. Consequently, some authors recommend
measuring the cTn levels at least once a year so, when an AMI is
suspected, the current cTn levels could be compared against the
‘‘baseline’’. Other authors do not advocate use of any ‘‘baseline’’
levels claiming they have very low diagnostic value [33]. The
most difﬁcult ﬁndings to assess are those of dialysis patients as
TnI levels after a dialysis session drop by almost 90%. While
troponin should not cross the dialysis membrane, it may be up
taken on its surface. By contrast, postdialysis troponin T levels
tend to rise, likely as a result of hemoconcentration. The
diagnosis of AMI in dialysis patients thus cannot be established
until after a more appreciable rise in cTn with a subsequent
relatively rapid decrease typical of AMI. It may be helpful to
assess the increase in levels after an interval of 1–3 h. The body
of experience with hs-cTn is still fairly limited.
Creatine kinase MB isoenzyme mass (CK-MB mass)
Creatine kinase MB isoenzyme is not myocardium-speciﬁc
occurring for instance in a small amount in skeletal muscle. Its
use in the diagnosis AMI is considered acceptable only in cases
where cTn assays are unavailable [4]. Although the 2011
European guidelines for the diagnosis of non-ST-elevation
acute coronary syndromes do no longer mention CK-MB, someinternational studies still require CK-MB mass determination.
While, similar to cTn, an increase in CK-MB mass is in most
cases diagnostic within 4–6 h of the onset of problems. The
levels normalize, despite extensive necrosis, as early as 48–
72 h. Creatine kinase MB mass may thus serve as an adjunct
marker for the diagnosis of reinfarction at a time when
circulating cTn levels are still high.
Catalytic activity of total creatine kinase (CK)
Due to its nonspeciﬁcity, determination of CK as a marker of
myocardial necrosis can currently only be used as an inexpen-
sive adjunct method to assess the dynamics and extent of
myocardial injury, e.g., in the patients after catheter-based
recanalization of an occluded artery in a diagnostically clear AMI.
Myoglobin
Given its relatively low molecular weight, in the presence of
myocyte injury, myoglobin escapes quickly into the circulation
to remain there, due to its short half-life, for only 10–30 min.
An increase in its plasma levels becomes apparent within 1 h
of the onset of the index event. An increase helpful in the early
diagnosis of AMI is apparent between hours 2 and 12 of the
event. However, myoglobin is not myocardium-speciﬁc and its
plasma levels tend to rise in renal failure. The cut-off values for
males and females differ and vary according to the manufac-
turer. Given the quick and relatively short rise, myoglobin is a
suitable adjunct marker in early diagnosis of AMI and
diagnosis of reinfarction.
Heart-type fatty acid-binding protein (h-FABP)
As this speciﬁc cardiac protein, which binds fatty acids, begins to
be released from an injured myocardium within 30 min of onset
of the index event, it should be used to quickly rule out AMI [34].
Using semiquantitative h-FABP examination with a point-of-
care test within 3 h of the ﬁrst manifestations of AMI, its
sensitivity in study conditions has been shown to be close to
70%, yet its performance in early diagnosis in everyday practice
is still lower [34,35]. Assays for h-FABP assessment by ELISA are
now available for the standard clinical use. There have been
reports showing that the predictive value of h-FABP in
recurrence of acute coronary syndrome and death may be
superior to standard cTn [36]. Couple of studies have suggested
that combining h-FABP with hs-cTn provides for an almost
negligible improvement insensitivity of early AMI diagnosis [37].
Isoenzyme BB glycogen phosphorylase (GPBB)
Yet another potential early biochemical marker of myocardial
necrosis is an increase in the plasma levels of GPBB. Within the
ﬁrst hour of the index event, GPBB determined by ELISA proved
to be the most sensitive indicator of myocardial injury with a
sensitivity of 96%, clearly superior to that of myoglobin (71%),
CK-MB mass (63%), and cTnT (54%) [38]. While its predictive
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speciﬁcity was very low (43.7%) [38]. In a study comparing point-
of-care assays, GPBB was a less sensitive marker than h-FABP.
Copeptin
Copeptin is the C-terminal prohormone arginine-vasopressin
(CT-proAVP). Unlike the arginine-vasopressin (antidiuretic
hormone), it is stable and consistently reﬂects any changes
in arginine-vasopressin circulating levels in response to a
variety of stimuli including AMI. Its plasma levels are
dependent on gender, renal function, and a host of other
factors. Copeptin levels correlate with left ventricular systolic
dysfunction. A meta-analysis of studies of baseline examina-
tions of the patients with suspected AMI showed the
sensitivity of copeptin alone of 63%, cTn alone 87%, yet a
combination of copeptin and cTn improved sensitivity for the
AMI diagnosis to 95–98%. Combining cTn with copeptin
decreased the speciﬁcity from 87% (when using cTn alone)
to 56%. On the other hand, a positive result of combined
copeptin and cTn determination did correlate with morbidity
and mortality. An increase in copeptin levels without a parallel
increase in cTn could help earlier focusing on other conditions
associated with some risk. As repeat examination of hs-cTn
after 3 h has a sensitivity of up to 100% and a high speciﬁcity,
routine introduction of copeptin examination for quick rule-
out of AIM currently seems to be quite unlikely [37,39–41].
Other markers of myocardial necrosis
At present, assays of several other sensitive biomarkers – e.g.,
cysteine and glycine-rich protein 3 (Csrp3) – are available that
can be used even in very early diagnosis of myocardial injury.
However, none of the novel markers have been to date used in
clinical practice for a variety of reasons, most importantly
because of technical complexity and high costs involved.
The strategy in suspected AMI
The ﬁrst cTn determination is performed immediately even in
patients with a short duration of complaints. Elevated cTn
levels may signal the onset of AMI earlier that one would guess
from the patient's medical history data or consider as just
another cause of the increase. In severe renal failure, early
blood analysis may also provide a baseline value for future
monitoring of the patient. Additional examinations to conﬁrm
the increase and subsequent decrease in cardiac markers at
standard cTn are recommended at an interval of 6–9 h, or
within 3 h of the ﬁrst hs-cTn assay. As the onset of complaints
may not coincide with that of myocardial necrosis, the
examination may need to be repeated.
Periprocedural AMI
For the diagnosis of AMI associated with percutaneous coronary
angioplasty (PCI), cTn levels should be >5 the 99th percentileURL in patients with nonelevated baseline values [5]. A rise of
cTn values >20% at 3 h is necessary for the diagnosis of the
periprocedural reinfarction if the baseline values are elevated
and are stable or falling. Smaller cTn values or smaller values
elevations would only suggest myocardial injury which is found
after an apparently uncomplicated elective PCI in up to a quarter
of patients. Some studies have suggested that a periprocedural
increase in cTn signiﬁcantly increases the risk of cardiovascular
complications including in-hospital death as well as cardiovas-
cular complications during follow-up [42–44]. A very mild
elevation heralds the risk of cardiovascular complications in
only the early postprocedural period [45]. Determination of
CK-MB mass with a shorter half-life of the increase is also
helpful for the diagnosis of periprocedural AMI [46].
For the diagnosis of AMI associated with cardiac surgery the
elevation of cardiac biomarker values should be >10 99th
percentile URL in case of baseline nonelevated values. A
smaller elevation again suggests only a periprocedural
myocardial necrosis [4,5,47]. Even a tenfold increase above
the URL is not infrequent.
It has been recently recommended to determine cTn even
after noncardiac surgery in at-risk patients over 45 years of age
and all those above 65 years. An increase in cTn on
postoperative days 1 and 2 is reported in 8% of the patients
who are usually without complaints and EKG alterations.
Unless there is another obvious cause, this cTn elevation is
considered a manifestation of ‘‘myocardial injury after
noncardiac surgery’’ (MINS). MINS is associated with markedly
increased risk of cardiovascular and 30-day mortality and
MINS patients require closer care [48].
Conclusion
Given their high sensitivity, speciﬁcity, and reasonable avail-
ability, cTn examinations are currently the gold standard of
biochemical diagnosis of myocyte necrosis whatever the
etiology [49,50]. Repeating an hs-cTn examination at 3 h will
provide a helpful clue in early diagnosis, diagnosis of recurrent
AMI and quick rule-out of AMI. Interpretation of mild elevations
of plasma cTn levels in healthy or apparently healthy
individuals poses a diagnostic challenge. All in all, the use
and utility of other biochemical markers, especially for the
purpose of early rule-out of AMI, are yet to be assessed in future.
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